Citadel Advisors’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Citadel Advisors’s Portfolio CSCI Stock Details CSCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2	Closed	-$15	–	15586
2023 Q4	$15	Buy	+2	New	+$15	﹤0.01%	14158
2022 Q1	–	Sell	-197	Closed	-$7K	–	14755
2021 Q4	$7K	Sell	197 -32	-14%	-$1.69K	﹤0.01%	13683
2021 Q3	$17K	Sell	229 -127	-36%	-$9.02K	﹤0.01%	13660
2021 Q2	$31K	Buy	356 +40	+13%	+$3.8K	﹤0.01%	13479
2021 Q1	$36K	Buy	+316	New	+$35K	﹤0.01%	12999
2019 Q3	–	Sell	-147	Closed	-$43K	–	9851
2019 Q2	$43K	Buy	147 +34	+30%	+$12K	﹤0.01%	8775
2019 Q1	$53K	Buy	+113	New	+$43.9K	﹤0.01%	8799

Other funds holding CSCI

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Citadel Advisors's CSCI Position: Q2 2024 in Review

Citadel Advisors sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q2 2024, closing a stake of 3,960 shares — an estimated $33.9K sold.

Citadel Advisors first reported a position in CSCI in Q4 2014 and held it in 16 quarters. The position peaked at $133K in Q1 2019. 13 funds tracked by Wall St. Rank hold CSCI as of Q2 2024.

Citadel Advisors reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Citadel Advisors sold 3,960 COSCIENS Biopharma Inc. Common Stock shares in Q2 2024, an estimated $33.9K.
Citadel Advisors first reported a position in COSCIENS Biopharma Inc. Common Stock in Q4 2014 and held it in 16 quarters.
Citadel Advisors's COSCIENS Biopharma Inc. Common Stock position peaked at $133K in Q1 2019.
13 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.